World

A number of Myeloma Sufferers in Center East Recognized Youthful Than International

A targeted literature review examining multiple myeloma across the Middle East and North Africa reveals that patients in the region are diagnosed at an earlier age than the global benchmark, while modern quadruplet regimens remain virtually absent from routine clinical practice despite guideline recommendations. Investigating data from Egypt, Saudi Arabia, Turkey, and the United Arab Emirates between 1 January 2015 and 30 May 2025, researchers screened 1,400 records across the PubMed and Embase databases alongside four supplementary gray-literature sources to evaluate regional disease burden, real-world interventions, and economic outcomes. A total of 94 publications satisfied formal eligibility criteria, comprising 64 peer-reviewed full-text articles and 30 conference abstracts. The evidentiary landscape is heavily dominated by retrospective observational designs, which accounted for 70.2 percent of identified studies, with more than half of all publications originating from medical centers in Turkey. Synthesized findings demonstrate that while the regional age-standardized incidence rate remains slightly lower than global figures, diagnosis consistently occurs between three and twenty-seven years earlier than international medians, pointing to distinct regional demographic characteristics and urgent clinical needs across participating health systems.

Epidemiological analyses identified an age-standardized incidence rate of 1.49 cases per 100,000 population across the Middle East and North Africa in 2019, reflecting a 14.95 percent increase between 1990 and 2019 that outpaced the global incidence rise of 10.99 percent over the same period. Incident cases were concentrated predominantly among mature adults, with individuals aged 50 to 70 years accounting for 53.87 percent of diagnoses, patients over 70 years representing 33.00 percent, and younger individuals aged 15 to 49 years making up 13.14 percent. Regional estimates from the International Agency for Research on Cancer GLOBOCAN repository recorded 2,827 incident cases in North Africa in 2022, corresponding to 1.5 percent of worldwide diagnoses and an age-standardized incidence rate of 1.3 per 100,000 individuals, stratified as 1.6 in men and 1.0 in women. Within Turkey, social insurance system records from the Sosyal Güvenlik Kurumu documented 10,146 treated cases between 2011 and 2017, averaging roughly 1,300 incident patients annually with a median diagnosis age between 63.8 and 66.1 years. Turkish male incidence rose significantly between 2001 and 2019, demonstrating an average annual percentage change of 5.63, whereas the increase among women remained statistically non-significant.

National incidence statistics diverged across surveillance registries and international modeling projections within the Arabian Peninsula and North Africa. In Saudi Arabia, GLOBOCAN models projected an age-standardized incidence rate of 1.02 per 100,000 individuals in 2020, yet domestic records from the Saudi Cancer Registry in 2022 documented higher rates of 2.3 per 100,000 in men and 1.4 per 100,000 in women among Saudi nationals. That single reporting year saw 127 male and 85 female cases diagnosed, with individuals aged 50 years and older comprising 79.2 percent of all registered diagnoses. Parallel GLOBOCAN evaluations reported 2020 age-standardized incidence rates of 0.89 per 100,000 in Egypt and 1.71 per 100,000 in the United Arab Emirates. Clinical manifestations at initial presentation consistently mirrored classic systemic complications defined by CRAB criteria, with skeletal involvement reported in 53.8 to 96.9 percent of study cohorts. However, comparative assessment of presentation profiles was constrained by disparate reporting criteria, as several cohorts tabulated mean biochemical parameters rather than proportioned symptom categorizations, obscuring precise clinical presentation trends across national settings.

Patient demographics across 69 real-world cohorts documented participant

Patient demographics across 69 real-world cohorts documented participant median ages ranging from 43 to 70 years, contrasting sharply with the global median onset age of 70 years. Among 13,083 newly diagnosed patients from 23 studies, median ages ranged between 45 and 70 years, while cohorts of 1,443 relapsed or refractory patients across 18 studies exhibited median ages between 49.6 and 69.5 years. A persistent male predominance emerged across 62 publications reporting sex distributions, with men comprising 55.9 percent of 17,477 cumulative patients, and national cohorts ranging between 55.4 and 75.0 percent male. Disease staging at clinical entry based on the International Staging System was detailed for 5,118 patients across 42 publications, revealing an overall distribution skewed toward advanced pathology: 41.4 percent presented with stage III disease, 32.6 percent presented with stage II, and 26.1 percent entered at stage I. Country-level stratifications showed that stage III was most prevalent in Saudi Arabia at 46.4 percent and Turkey at 38.6 percent, whereas stage I was most common in Egypt at 42.8 percent, and stage II led single-center cohorts in the United Arab Emirates at 46.4 percent.

Cytogenetic risk stratification was severely underreported across the collected regional literature, appearing in only 25 of the 94 identified publications with substantial proportions of incomplete data. The most frequently tracked chromosomal abnormalities included deletion 17p in nine publications, deletion 13q in eight publications, and translocation t(4;14) in eight publications, yet testing panels varied widely between institutions. Treatment pattern evaluations involving 12,200 patients across 19 observational studies revealed that the proteasome inhibitor bortezomib formed the foundation of clinical care, administered to 49.7 percent of all patients regardless of therapy line. Regimens incorporating the immunomodulatory agent lenalidomide ranked second at 22.8 percent, while traditional cytotoxic chemotherapy combinations constituted 13.2 percent. National therapeutic distributions showed consistent bortezomib adoption ranging from 49.3 to 100 percent across territories, though second-line selections diverged: lenalidomide served as the second most frequent option in Egypt, Turkey, and the United Arab Emirates, whereas unselected cytotoxic chemotherapy represented the second most common approach in Saudi Arabian registries.

Induction practices in newly diagnosed multiple myeloma relied primarily on triplet combinations, whereas advanced quadruplet regimens remained exceedingly scarce. Among 11,152 newly diagnosed individuals, bortezomib-containing regimens were utilized in 49.2 percent, lenalidomide in 23.5 percent, and chemotherapy in 12.8 percent. Across studies detailing specific multi-agent combinations from 1995 to 2023, the triplet combination of bortezomib, cyclophosphamide, and dexamethasone was administered to 37.5 percent of patients overall and 48.1 percent of newly diagnosed individuals, followed by vincristine, doxorubicin, and dexamethasone at 11.6 percent. Modern quadruplets combining anti-CD38 monoclonal antibodies with immunomodulatory and proteasome inhibitors accounted for only 0.92 percent of real-world use, isolated entirely to the multicenter REPAIR registry across Gulf tertiary centers. The REPAIR study, analyzing 148 relapsed patients, revealed that first-line induction regimens remained comparable between transplant-eligible and transplant-ineligible patients, with bortezomib prescribed to 47 and 42 percent and lenalidomide to 33 and 36 percent, respectively, while thalidomide was reserved primarily for non-transplant cohorts. In later treatment lines, therapy transitioned toward daratumumab, which reached 44.5 percent utilization among relapsed or refractory cohorts.

Efficacy assessments demonstrated high immediate tumor response rates

Efficacy assessments demonstrated high immediate tumor response rates that deteriorated progressively with successive lines of therapy. In newly diagnosed cohorts, overall response rates ranged from 60.3 to 80.0 percent in Turkish investigations and reached 83 percent in Saudi Arabian cohorts, with complete responses recorded between 21.1 and 37 percent. In relapsed or refractory populations encompassing 1,201 patients across 13 investigations, overall response rates ranged from 35.0 to 72.5 percent, with complete responses observed in 2.4 to 28.8 percent. Sequential tracking within the REPAIR study demonstrated steep therapeutic attrition across lines: overall response rates dropped from 79.0 percent in first-line therapy to 62.2 percent in second-line, 45.7 percent in third-line, and 12.4 percent in fourth-line management, accompanied by corresponding complete response declines from 47.9 percent to 6.2 percent. Among patients receiving daratumumab-based salvage, objective responses occurred in 35.9 to 59.4 percent of participants, including heavily pretreated cohorts. Similarly, lenalidomide salvage elicited overall response rates of 62.9 percent when initiated at second line, which fell to 16.1 percent in third line and 6.5 percent in fourth line or beyond.

Progression-free survival varied dramatically based on disease staging, stem cell transplantation, and underlying cytogenetic mutations across 24 tracking publications. Median progression-free survival spanned from 2 to 97.7 months across all cohorts, with newly diagnosed patients achieving medians of 14 to 97.7 months, while relapsed or refractory cohorts recorded medians between 2 and 38.1 months. Autologous stem cell transplantation conferred pronounced survival advantages, supporting median progression-free durations of 20 to 97.7 months among 592 recipients across six studies. In an Egyptian single-center analysis, high-risk chromosomal lesions precipitated inferior outcomes: patients harboring translocation t(4;14) exhibited significantly shorter median time to progression compared to non-carriers, measuring 36.0 versus 88.5 months, while deletion 17p conferred a median progression-free survival of 23.3 months versus 52.94 months in standard-risk patients. Induction comparisons in Turkey demonstrated median progression-free survival durations of 97.7 months with bortezomib, cyclophosphamide, and dexamethasone versus 67.1 months with bortezomib and dexamethasone alone, yielding comparable five-year progression-free rates of 59 and 56 percent.

Overall survival across 27 reporting studies ranged from 4 to 125.3 months, influenced heavily by age, surgical intervention, and cytogenetic lesions. Newly diagnosed populations achieved median overall survival spanning 22 to 122.2 months, compared to 4 to 60.5 months in relapsed cohorts. High-risk cytogenetics dramatically shortened life expectancy; Egyptian cohort data documented median overall survival of 36.6 months in patients with translocation t(4;14) versus 85.0 months in wild-type cases, while deletion 17p curtailed overall survival to 35.5 months versus 81.0 months. Cumulative chromosomal abnormalities compounded mortality, reducing median overall survival from 57 months with zero high-risk markers to 32 months with one marker and 6 months with two markers. Patient-reported quality of life evaluations in Turkey and Saudi Arabia highlighted persistent somatic distress, with 50 percent of patients with chemotherapy-induced neuropathy experiencing debilitating bone pain that escalated with physical activity. Interventional spinal procedures substantially alleviated functional disability: surgical vertebroplasty and kyphoplasty for spinal fractures reduced mean visual analog pain scores from 8.75 preoperatively to 3.21 at hospital discharge, alongside marked gains in functional musculoskeletal scores.

Safety reviews covering 27 publications identified frequent hematologic

Safety reviews covering 27 publications identified frequent hematologic cytopenias, peripheral neuropathy, and gastrointestinal disturbances, with generic formulations showing clinical safety and therapeutic parity to branded originals. High-grade neutropenia and thrombocytopenia occurred regularly with daratumumab regimens, while peripheral neuropathy affected 11.3 to 50 percent of bortezomib-treated individuals, prompting dose modifications in 31 percent. Direct comparative trials confirmed equivalent efficacy and adverse event profiles between generic and branded formulations of bortezomib, lenalidomide, and conditioning melphalan. Healthcare resource utilization evaluations from five regional studies demonstrated substantial financial burdens, with weighted average annual direct costs reaching 125,000 to 372,000 US dollars per patient in the Gulf. Regional guidelines from Saudi Arabia and Turkey now recommend upfront anti-CD38 quadruplets, creating a noticeable gap with current real-world practice where quadruplet adoption remains below one percent due to reimbursement constraints. The authors conclude that persistent reliance on single-center retrospective datasets, variable cytogenetic screening, and delayed integration of novel therapies underline the need for prospective multi-country registries to improve multiple myeloma care across the region.

Subject of Research: Regional disease burden, clinical outcomes, treatment patterns, and healthcare reorth Africa

Article Title: Burden of Disease, Treatment Patterns, and Healthcare Re Africa Region: A Targeted Literature Review

Article References: Beksac, M., Samra, M., Abduljalil, O., AAL Yaseen, H., Besisik, S., Seval, G. C., Elghandour, A., Fathy, G., Özsan, G. H., Marashi, M., Sevindik, Ö. G., Taha, R. Y. I., Aggarwal, B., Mouro, J., & Phansalkar, A. (2026). Burden of Disease, Treatment Patterns, and Healthcare Re Africa Region: A Targeted Literature Review. Oncology and Therapy, 14(2), 449-498. https://doi.org/10.1007/s40487-026-00428-9

DOI:10.1007/s40487-026-00428-9

Keywords: multiple myeloma, Middle East and North Africa, bortezomib, lenalidomide, daratumumab, age-standardized incidence rate, International Staging System, autologous stem cell transplantation, progression-free survival, overall survival, quadruplet regimens, healthcare rey, retrospective observational studies, hematologic malignancy

News. Multiple Myeloma Patients in Middle East Diagnosed Younger Than Global Average. Scienmag

Source: bioengineer.org

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button